Chronic L-Dopa decreases serotonin neurons in a subregion of the dorsal raphe nucleus

Journal of Pharmacology and Experimental Therapeutics

Volumn 351, Issue 2, 2014, Pages 440-447

  Stansley, Branden J ^a   Yamamoto, Bryan K ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; ASCORBIC ACID; BENSERAZIDE; DOPAMINE; LEVODOPA; SELEGILINE; SEROTONIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL LOSS; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; DRUG ANTAGONISM; FOREBRAIN; FRONTAL CORTEX; LONG TERM CARE; MALE; MONOTHERAPY; NONHUMAN; OXIDATIVE STRESS; PREFRONTAL CORTEX; RAT; SEROTONIN RELEASE; SEROTONINERGIC NERVE CELL; TREATMENT RESPONSE; ANIMAL; DRUG EFFECT; METABOLISM; NERVE CELL; RAPHE NUCLEUS; SPRAGUE DAWLEY RAT;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; DOPAMINE; LEVODOPA; MALE; NEURONS; OXIDATIVE STRESS; PREFRONTAL CORTEX; RAPHE NUCLEI; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN;

EID: 84908125017     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.218966     Document Type: Article

References (52)

1. Agus DB, Gambhir SS, Pardridge WM, Spielholz C, Baselga J, Vera JC, and Golde DW (1997) Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters. J Clin Invest. 100:2842-2848.
2. Albert PR, Vahid-Ansari F, and Luckhart C (2014) Serotonin-prefrontal cortical circuitry in anxiety and depression phenotypes: pivotal role of pre- and postsynaptic 5-HT1A receptor expression. Front Behav Neurosci. 8:199.
3. Amat J, Baratta MV, Paul E, Bland ST, Watkins LR, and Maier SF (2005) Medial prefrontal cortex determines how stressor controllability affects behavior and dorsal raphe nucleus. Nat Neurosci. 8:365-371.
4. Arai R, Karasawa N, Geffard M, Nagatsu T, and Nagatsu I (1994) Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous l-DOPA in the rat, with reference to the involvement of aromatic L-amino acid decarboxylase. Brain Res. 667:295-299.
5. Bertler A, Falck B, and Rosengren E (1963) The Direct Demonstration of a Barrier Mechanism in the Brain Capillaries. Acta Pharmacol Toxicol (Copenh). 20:317-321.
6. Bezard E, Hill MP, Crossman AR, Brotchie JM, Michel A, Grimée R, and Klitgaard H (2004) Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. Eur J Pharmacol. 485:159-164.
7. Birkmayer W and Hornykiewicz O (1962) The L-dihydroxyphenylalanine (L-DOPA) effect in Parkinson's syndrome in man: on the pathogenesis and treatment of Parkinson akinesis. [article in German] Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr. 203:560-574.
8. Bishop S, Duncan J, Brett M, and Lawrence AD (2004) Prefrontal cortical function and anxiety: controlling attention to threat-related stimuli. Nat Neurosci. 7:184-188.
9. Borah A and Mohanakumar KP (2007) Long-term L-DOPA treatment causes indiscriminate increase in dopamine levels at the cost of serotonin synthesis in discrete brain regions of rats. Cell Mol Neurobiol. 27:985-996.
10. Camp DM, Loeffler DA, and LeWitt PA (2000) L-DOPA does not enhance hydroxyl radical formation in the nigrostriatal dopamine system of rats with a unilateral 6-hydroxydopamine lesion. J Neurochem. 74:1229-1240.
11. Carlsson A (2002) Treatment of Parkinson's with L-DOPA. The early discovery phase, and a comment on current problems. J Neural Transm. 109:777-787.
12. Carlsson T, Carta M, Winkler C, Björklund A, and Kirik D (2007) Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J Neurosci. 27:8011-8022.
13. Carta M, Carlsson T, Kirik D, and Björklund A (2007) Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain. 130:1819-1833.
14. Choi C, Sohn YH, Lee JH, and Kim J (2000) The effect of long-term levodopa therapy on depression level in de novo patients with Parkinson's disease. J Neurol Sci. 172:12-16.
15. Damãsio AR, Lobo-Antunes J, and Macedo C (1971) Psychiatric aspects in Parkinsonism treated with L-dopa. J Neurol Neurosurg Psychiatry. 34:502-507.
16. Engeln M, De Deurwaerdère P, Li Q, Bezard E, and Fernagut PO (2014) Widespread monoaminergic dysregulation of both motor and non-motor circuits in parkinsonism and dyskinesia. Cereb Cortex DOI: 10.1093/cercor/bhu076 [published ahead of print].
17. Eskow Jaunarajs KL, Angoa-Perez M, Kuhn DM, and Bishop C (2011) Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment. Neurosci Biobehav Rev. 35:556-564.
18. Eskow Jaunarajs KL, Dupre KB, Ostock CY, Button T, Deak T, and Bishop C (2010) Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat. Behav Pharmacol. 21:627-637.
19. Eskow Jaunarajs KL, George JA, and Bishop C (2012) L-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson's disease. Neuroscience. 218:243-256 DOI: 10.1016/j. neuroscience.2012.05.052.
20. Fernandez HH and Chen JJ (2007) Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. Pharmacotherapy. 27:174S-185S.
21. Forster GL, Feng N, Watt MJ, Korzan WJ, Mouw NJ, Summers CH, and Renner KJ (2006) Corticotropin-releasing factor in the dorsal raphe elicits temporally distinct serotonergic responses in the limbic system in relation to fear behavior. Neuroscience. 141:1047-1055.
22. Graham DG (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol. 14:633-643.
23. Hashimoto S, Inoue T, and Koyama T (1999) Effects of conditioned fear stress on serotonin neurotransmission and freezing behavior in rats. Eur J Pharmacol. 378:23-30.
24. Hastings TG, Lewis DA, and Zigmond MJ (1996) Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc Natl Acad Sci USA. 93:1956-1961.
25. Hauser RA (2009) Levodopa: past, present, and future. Eur Neurol. 62:1-8.
26. Ishida Y, Hashiguchi H, Todaka K, Ishizuka Y, and Mitsuyama Y (2000) Repeated administration of high dose levodopa enhances hydroxyl radical production in the rat striatum denervated with 6-hydroxydopamine. Neurosci Lett. 290:33-36.
27. Juorio AV, Li XM, Walz W, and Paterson IA (1993) Decarboxylation of L-dopa by cultured mouse astrocytes. Brain Res. 626:306-309.
28. Kannari K, Tanaka H, Maeda T, Tomiyama M, Suda T, and Matsunaga M (2000) Reserpine pretreatment prevents increases in extracellular striatal dopamine following L-DOPA administration in rats with nigrostriatal denervation. J Neurochem. 74:263-269.
29. Kuhn DM and Arthur R, Jr (1998) Dopamine inactivates tryptophan hydroxylase and forms a redox-cycling quinoprotein: possible endogenous toxin to serotonin neurons. J Neurosci. 18:7111-7117.
30. Lindgren HS, Andersson DR, Lagerkvist S, Nissbrandt H, and Cenci MA (2010) L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. J Neurochem. 112:1465-1476.
31. Lowry CA, Hale MW, Evans AK, Heerkens J, Staub DR, Gasser PJ, and Shekhar A (2008) Serotonergic systems, anxiety, and affective disorder: focus on the dorsomedial part of the dorsal raphe nucleus. Ann N Y Acad Sci. 1148:86-94.
32. Lowry CA, Johnson PL, Hay-Schmidt A, Mikkelsen J, and Shekhar A (2005) Modulation of anxiety circuits by serotonergic systems. Stress. 8:233-246.
33. Marsden CD (1994) Problems with long-term levodopa therapy for Parkinson's disease. Clin Neuropharmacol 17(Suppl 2):S32-S44.
34. Mena MA, Pardo B, Casarejos MJ, Fahn S, and García de Yébenes J (1992) Neurotoxicity of levodopa on catecholamine-rich neurons. Mov Disord. 7:23-31.
35. Mendlewicz J and Youdim MB (1983) L-Deprenil, a selective monoamine oxidase type B inhibitor, in the treatment of depression: a double blind evaluation. Br J Psychiatry. 142:508-511.
36. Miller DW and Abercrombie ED (1999) Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous L-DOPA: studies in intact and 6-hydroxydopaminetreated rats. J Neurochem. 72:1516-1522.
37. Navailles S, Benazzouz A, Bioulac B, Gross C, and De Deurwaerdère P (2010a) Highfrequency stimulation of the subthalamic nucleus and L-3, 4-dihydroxyphenylalanine inhibit in vivo serotonin release in the prefrontal cortex and hippocampus in a rat model of Parkinson's disease. J Neurosci. 30:2356-2364.
38. Navailles S, Bioulac B, Gross C, and De Deurwaerdère P (2010b) Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease. Neurobiol Dis. 38:136-143.
39. Navailles S, Bioulac B, Gross C, and De Deurwaerdère P (2011a) Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease. Neurobiol Dis. 41:585-590.
40. Navailles S, Carta M, Guthrie M, and De Deurwaerdère P (2011b) L-DOPA and serotonergic neurons: functional implication and therapeutic perspectives in Parkinson's disease. Cent Nerv Syst Agents Med Chem. 11:305-320.
41. Ng KY, Chase TN, Colburn RW, and Kopin IJ (1970) L-Dopa-induced release of cerebral monoamines. Science. 170:76-77.
42. Paxinos G and Watson C (1997) The Rat Brain in Stereotaxic Coordinates, 3rd ed Academic Press, San Diego, CA.
43. Porras G, De Deurwaerdere P, Li Q, Marti M, Morgenstern R, Sohr R, Bezard E, Morari M, and Meissner WG (2014) L-Dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum. Sci Rep. 4:3730.
44. Riederer P and Laux G (2011) MAO-inhibitors in Parkinson's disease. Exp Neurobiol. 20:1-17.
45. Spina MB and Cohen G (1989) Dopamine turnover and glutathione oxidation: implications for Parkinson disease. Proc Natl Acad Sci USA. 86:1398-1400.
46. Stansley BJ and Yamamoto BK (2013) L-Dopa-induced dopamine synthesis and oxidative stress in serotonergic cells. Neuropharmacology. 67:243-251.
47. Tanaka H, Kannari K, Maeda T, Tomiyama M, Suda T, and Matsunaga M (1999) Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport. 10:631-634.
48. Van Bockstaele EJ, Biswas A, and Pickel VM (1993) Topography of serotonin neurons in the dorsal raphe nucleus that send axon collaterals to the rat prefrontal cortex and nucleus accumbens. Brain Res. 624:188-198.
49. Warden MR, Selimbeyoglu A, Mirzabekov JJ, Lo M, Thompson KR, Kim SY, Adhikari A, Tye KM, Frank LM, and Deisseroth K (2012) A prefrontal cortex-brainstem neuronal projection that controls response to behavioural challenge. Nature. 492:428-432.
50. Yee RE, Cheng DW, Huang SC, Namavari M, Satyamurthy N, and Barrio JR (2001) Blood-brain barrier and neuronal membrane transport of 6-[18F]fluoro-L-DOPA. Biochem Pharmacol. 62:1409-1415.
51. Youdim MB and Bakhle YS (2006) Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol 147(Suppl 1):S287-S296.
52. Zhu MY, Juorio AV, Paterson IA, and Boulton AA (1994) Regulation of aromatic L-amino acid decarboxylase in rat striatal synaptosomes: effects of dopamine receptor agonists and antagonists. Br J Pharmacol. 112:23-30.